Form 4: Arteris COO Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, sold a total of 35,137 shares of common stock in early December 2025 under a pre-arranged 10b5-1 trading plan.
Summary
- Laurent R. Moll, Chief Operating Officer of Arteris, Inc. (AIP), reported sales of common stock.
- On December 5, 2025, Moll sold 17,200 shares of common stock at a weighted average price of $16.9687 per share, with prices ranging from $16.90 to $17.04.
- On December 8, 2025, Moll sold an additional 17,937 shares of common stock at a weighted average price of $17.9201 per share, with prices ranging from $17.90 to $17.97.
- These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Moll on March 12, 2025.
- Following these transactions, Moll directly beneficially owns 275,159 shares of Arteris, Inc. common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions were conducted under a pre-arranged 10b5-1 trading plan, which typically indicates a scheduled divestment strategy rather than a reaction to immediate company performance or outlook.
Negatives
- The Chief Operating Officer sold a significant number of shares (35,137 total) over two trading days.
Industry Context
This filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. Insider sales under 10b5-1 plans are common practice for executives to manage personal finances while complying with insider trading regulations.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2025, demonstrating adherence to insider trading regulations. | 03/12/2025 | Enhances transparency regarding insider stock sales, indicating pre-planned divestment rather than opportunistic trading. |
Stakeholder Impact
- Shareholders may note the sale of shares by a key executive, though the 10b5-1 plan context generally mitigates concerns about management's confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date the Rule 10b5-1 trading plan was adopted by Laurent R. Moll. |
| 12/05/2025 | Date of transaction where 17,200 shares of common stock were sold. |
| 12/08/2025 | Date of transaction where 17,937 shares of common stock were sold. |
| 12/09/2025 | Date the Form 4 was signed by Paul Alpern, as Attorney-in-Fact for Laurent R. Moll. |
Keywords
Arteris, AIP, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Laurent R. Moll, Chief Operating Officer, Equity Sales
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.